Pharmaceutical and biotechnology companies are required to maintain continuous readiness for global inspections by the US FDA, the UK MHRA, EU regulatory authorities, and other relevant bodies. Although some inspections are pre-scheduled, FDA inspections often occur without prior notice, making it essential for organisations to maintain a robust Quality Management System (QMS) and a well-trained inspection team.
A leading Indian pharmaceutical company, operating across the US, the UK, Germany, Canada, and Russia, with experience in major therapeutic areas such as cardiovascular, CNS, gastrointestinal, and anti-diabetic segments, received an FDA notification for a PV inspection, with only 3 days to prepare.
Their specific challenges included:
The company engaged APCER’s QA team for urgent inspection readiness support. Despite the short notice, APCER implemented a structured, end-to-end approach, which included conducting a gap analysis, forming a Core Inspection Management Team of 13 key stakeholders, organising mock interviews, hosting training, and managing all logistics. APCER successfully hosted the entire 4-day inspection, with on-site presence at the client’s US office.
The FDA inspection concluded with no Form 483 observations. The inspectors commended the team’s professionalism, and the client expressed high satisfaction with APCER’s overall inspection management.
APCER delivered the results through a structured approach: